PCM
IONS icon

Penserra Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Penserra Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-471
Closed -$22K – 697
2016
Q4 		$22K Buy
471
+81
+21% +$3.21K ﹤0.01% 571
2016
Q3 		$14K Buy
390
+156
+67% +$4.88K ﹤0.01% 748
2016
Q2 		$5K Buy
234
+84
+56% +$2.71K ﹤0.01% 867
2016
Q1 		$6 Buy
150
+32
+27% +$1.3K ﹤0.01% 672
2015
Q4 		$7K Buy
+118
New +$6.37K ﹤0.01% 630

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Penserra Capital Management's IONS Position: Q1 2017 in Review

Penserra Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2017, closing a stake of 471 shares — an estimated $22K sold.

Penserra Capital Management first reported a position in IONS in Q4 2015 and held it in 5 quarters. The position peaked at $22K in Q4 2016. 270 funds tracked by Wall St. Rank hold IONS as of Q1 2017.

  • Penserra Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Penserra Capital Management sold 471 Ionis Pharmaceuticals shares in Q1 2017, an estimated $22K.
  • Penserra Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • Penserra Capital Management's Ionis Pharmaceuticals position peaked at $22K in Q4 2016.
  • 270 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2017.

Based on Penserra Capital Management's 13F filing for Q1 2017, filed 9 May 2017.